Personalized warfarin therapy developed

Feb. 26, 2010 at 3:13 PM

COLUMBUS, Ohio, Feb. 26 (UPI) -- U.S. researchers say their new rapid, genotyping method can help clinicians choose appropriate doses of the blood thinner warfarin for individual patients.

Researchers at Ohio State University in Columbus, led by Dr. Haifeng Wu, say their rapid, genotyping method can identify the single nucleotide polymorphisms that affect use of warfarin -- a drug commonly prescribed to prevent blood clots.

Warfarin, also known as Coumadin, needs to be closely monitored because dosing is complicated by interactions with some foods and other drugs, Wu says.

"On-site application of this method in hospital laboratories will greatly help clinicians to determine appropriate doses of warfarin to treat patients with thromboembolic disorders," study authors said in a statement.

The study was published in the Journal of Molecular Diagnostics.

Related UPI Stories
Latest Headlines
Trending Stories
Females with childhood ADHD at double the risk for obesity
Medicaid-paid births up in Texas since defunding Planned Parenthood
New ethics standards for DNA replacement therapies
New screening method detects all cystic fibrosis mutations
Esophageal cooling device helps doctors control body temperature